Evelo Biosciences, Inc.
EVLODelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001694665
Evelo Biosciences, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Nov 8, 2023; 29 institutions reported holding it in 13F filings for Q3 2023, worth $52.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q3 2023, +4 vs. previous quarter
- 13F value
- $52.0M
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding EVLO, Q3 2023
No superinvestor reported holding EVLO at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by Evelo Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 8, 2023 (view filing)8:32 PM ET | Nov 8 | Same day | Bodmer MarkCSO, President of R&D | SSale | −3.16K | $0.33 | −$1.04K | −10.9%25.7K after | 10b5-1 |
| Nov 8, 2023 (view filing)8:32 PM ET | Nov 8 | Same day | McHale DuncanChief Medical Officer | SSale | −3.10K | $0.33 | −$1.02K | −15.4%17.0K after | 10b5-1 |
| Nov 8, 2023 (view filing)8:31 PM ET | Nov 8 | Same day | Gill SimbaPresident & CEO | SSale | −172 | $0.33 | −$56.76 | −1.0%17.8K after | 10b5-1 |
| Nov 8, 2023 (view filing)8:31 PM ET | Nov 8 | Same day | Thorell MarellaChief Financial Officer | SSale | −1.81K | $0.33 | −$597.63 | −7.5%22.3K after | 10b5-1 |
| Nov 3, 2023 (view filing)4:12 PM ET | Nov 2 | 1 day | Bodmer MarkCSO, President of R&D | SSale | −6.85K | $0.33 | −$2.26K | −23.5%22.3K after | 10b5-1 |
| Nov 3, 2023 (view filing)4:11 PM ET | Nov 2 | 1 day | McHale DuncanChief Medical Officer | SSale | −6.85K | $0.33 | −$2.26K | −33.5%13.6K after | 10b5-1 |
| Nov 3, 2023 (view filing)4:11 PM ET | Nov 2 | 1 day | Thorell MarellaChief Financial Officer | SSale | −4.00K | $0.33 | −$1.32K | −18.5%17.6K after | 10b5-1 |
| Sep 29, 2023 (view filing) | Sep 28 | 1 day | Gill SimbaPresident & CEO | SSale | −2.00K | $3.94 | −$7.86K | −10.6%16.8K after | 10b5-1 |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Bodmer MarkCSO, President of R&D | SSale | −3.13K | $9.51 | −$29.7K | −15.8%16.6K after | 10b5-1 |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Gill SimbaPresident & CEO | SSale | −342 | $9.51 | −$3.25K | −8.3%3.75K after | 10b5-1 |
Top 10 13F holders, Q3 2023
The largest institutional positions in Evelo Biosciences, Inc. at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 7,932,624 | $31.1M | 2.26% | +5,411,255+214.6% | Added |
| FMR LLC | 2,446,390 | $9.59M | 0.00% | +2,319,965+1,835.1% | Added |
| HarbourVest Partners LLC | 1,451,876 | $5.69M | 1.93% | +1,298,701+847.9% | Added |
| Vanguard Group Inc | 357,711 | $1.40M | 0.00% | +201,815+129.5% | Added |
| Alyeska Investment Group, L.P. | 265,103 | $1.04M | 0.01% | +265,103 | New |
| State of Michigan Retirement System | 203,536 | $797.9K | 0.01% | 00.0% | Unchanged |
| Credit Suisse AG | 200,000 | $784.0K | 0.00% | +19,480+10.8% | Added |
| BlackRock Inc. | 127,743 | $500.8K | 0.00% | +74,204+138.6% | Added |
| Geode Capital Management, LLC | 64,823 | $254.2K | 0.00% | +35,751+123.0% | Added |
| Alphabet Inc. | 53,024 | $207.9K | 0.01% | 00.0% | Unchanged |